1. Home
  2. DBVT vs CCRD Comparison

DBVT vs CCRD Comparison

Compare DBVT & CCRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DBVT
  • CCRD
  • Stock Information
  • Founded
  • DBVT 2002
  • CCRD 1973
  • Country
  • DBVT France
  • CCRD United States
  • Employees
  • DBVT N/A
  • CCRD N/A
  • Industry
  • DBVT Biotechnology: Biological Products (No Diagnostic Substances)
  • CCRD
  • Sector
  • DBVT Health Care
  • CCRD
  • Exchange
  • DBVT Nasdaq
  • CCRD Nasdaq
  • Market Cap
  • DBVT 260.5M
  • CCRD 215.8M
  • IPO Year
  • DBVT N/A
  • CCRD N/A
  • Fundamental
  • Price
  • DBVT $9.87
  • CCRD $26.81
  • Analyst Decision
  • DBVT Buy
  • CCRD Hold
  • Analyst Count
  • DBVT 4
  • CCRD 1
  • Target Price
  • DBVT $14.81
  • CCRD $21.00
  • AVG Volume (30 Days)
  • DBVT 33.2K
  • CCRD 55.5K
  • Earning Date
  • DBVT 11-05-2025
  • CCRD 10-30-2025
  • Dividend Yield
  • DBVT N/A
  • CCRD N/A
  • EPS Growth
  • DBVT N/A
  • CCRD 432.93
  • EPS
  • DBVT N/A
  • CCRD 0.99
  • Revenue
  • DBVT $3,800,000.00
  • CCRD $64,808,000.00
  • Revenue This Year
  • DBVT $1,743.46
  • CCRD $17.35
  • Revenue Next Year
  • DBVT $1,045.66
  • CCRD N/A
  • P/E Ratio
  • DBVT N/A
  • CCRD $26.97
  • Revenue Growth
  • DBVT N/A
  • CCRD 23.61
  • 52 Week Low
  • DBVT $2.21
  • CCRD $12.12
  • 52 Week High
  • DBVT $12.78
  • CCRD $31.99
  • Technical
  • Relative Strength Index (RSI)
  • DBVT 55.10
  • CCRD 44.76
  • Support Level
  • DBVT $9.58
  • CCRD $26.65
  • Resistance Level
  • DBVT $10.50
  • CCRD $27.38
  • Average True Range (ATR)
  • DBVT 0.51
  • CCRD 0.55
  • MACD
  • DBVT 0.07
  • CCRD -0.05
  • Stochastic Oscillator
  • DBVT 64.92
  • CCRD 11.03

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

About CCRD CoreCard Corporation

CoreCard Corp is engaged in the business of providing technology solutions and processing services to the financial technology and services market. It designs, develops and markets a comprehensive suite of software solutions to program managers, accounts receivable businesses, financial institutions, retailers and processors to manage their credit and debit cards, prepaid cards, private label cards, fleet cards, buy now pay later programs, loyalty programs and accounts receivable and loan transactions. The CoreCard software platform and modules include CoreENGINE, CoreISSUE, CoreFRAUD, CoreCOLLECT, CoreAPP, CoreMONEY and CoreACQUIRE. Its customers are located in the U.S, European Union and the Middle East of which key revenue is derived from the U.S.

Share on Social Networks: